Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Amputation can be prevented when patients are treated by podiatric physicians: Study

Amputation, one of the most devastating and costly consequences of diabetes, can be prevented when patients are treated by podiatric physicians. That's the finding of a national, large-scale study co-authored by Dr. James Wrobel, DPM, MS, Associate Professor of Medicine at Rosalind Franklin University of Medicine and Science.

5 Aug 2010

Scientist invents new approach to boost body's response to vaccinations

As the medical community searches for better vaccines and ways to deliver them, a University of Rochester scientist believes he has discovered a new approach to boosting the body's response to vaccinations.Richard P. Phipps, Ph.D., found that the same molecules used in drugs that treat diabetes also stimulate B cells in the immune system, pushing them to make antibodies for protection against invading microorganisms.

5 Aug 2010

FDA designates XOMA 052 orphan drug for Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.

5 Aug 2010

Arthritis treatment costs more than $128 billion a year in the U.S.

Arthritis is the single greatest cause of chronic pain and disability among Americans and the treatment of arthritis costs the nation more than $128 billion a year in medical care and lost earnings. Persistent, chronic joint pain determines the choices people make and limits their ability to perform basic tasks for themselves and their family. Eighty percent of Americans either have, or know someone who has, arthritis and these numbers continue to escalate.

4 Aug 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results.

4 Aug 2010

Targacept licenses Cornerstone technology for inflammatory disorders program

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced that it has added to its program for inflammatory disorders by entering into an exclusive worldwide license agreement with Cornerstone Therapeutics Inc. The agreement grants Targacept rights to Cornerstone's NNR-based patents, as well as its library of preclinical compounds that act on the alpha7 or other nicotinic receptors.

4 Aug 2010

Savient second-quarter net loss decreases to $5.0 million

Savient Pharmaceuticals, Inc. reported financial results for the three and six months ended June 30, 2010. The net loss for the second quarter of 2010 was $5.0 million, or $0.07 per basic and diluted share, on total revenues of $1.0 million, compared with a net loss of $54.8 million, or $0.92 per basic and diluted share on total revenues of $0.7 million for the second quarter of 2009.

4 Aug 2010

Researchers identify TACI; MyD88 activates immune system against infection

Researchers from Mount Sinai School of Medicine have found a new mechanism that explains how certain immune cells are activated to create protective antibodies against infections or pathological antibodies such as those present in autoimmune diseases like lupus and rheumatoid arthritis. The research is published online in the September issue of Nature Immunology.

4 Aug 2010

Horizon Pharma files registration statement with U.S. SEC for proposed initial public offering

Horizon Pharma, Inc. announced today that it has filed a registration statement on form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the Company.

4 Aug 2010

POZEN reports $16.2M net income for second-quarter 2010

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the second quarter ended June 30, 2010.

3 Aug 2010

Rigel reports net income of $27.0M for second-quarter 2010

Rigel Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2010.

3 Aug 2010

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that clinical trials ongoing in the U.S. using umbilical cord blood in the treatment of cerebral palsy, high-risk hematologic cancer, injured spinal cords and Type 1 diabetes provide significant further evidence of the importance of storing umbilical cord blood at the time of birth.

3 Aug 2010

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal, shows how modified melittin may revolutionize treatments for cancer and perhaps other conditions, such as arthritis, cardiovascular disease, and serious infections.

3 Aug 2010

$International study of more than 60,000 women highlights additional risk associated with fractures$

International study of more than 60,000 women highlights additional risk associated with fractures

Researchers seeking to understand the impact of osteoporosis and fractures on various aspects of health have found that women who had previous fractures experienced a significant reduction in health-related quality of life similar to or worse than that experienced by patients with diabetes, arthritis, lung disease and other chronic illnesses. This latest study from the Global Longitudinal Study of Osteoporosis in Women (GLOW), which is based at the Center for Outcomes Research at the University of Massachusetts Medical School, was published online.

3 Aug 2010

Disparities in cardiovascular disease risk linked to socioeconomic differences between races: Study

A new UCLA study suggests that disparities in cardiovascular disease risk in the United States are due less to race or ethnicity than to socioeconomic status.

2 Aug 2010

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Osteologix, Inc. through its wholly owned Irish subsidiary Osteologix Limited and the Servier Research Group, the leading French independent pharmaceutical company, today announced that Osteologix has granted Servier an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. NB S101 is an innovative molecule acting on both bone formation and bone resorption.

2 Aug 2010

Lexicon acquires equity shares of Symphony Icon Holdings

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today announced that it has exercised a restructured purchase option under its drug development financing collaboration with Symphony Icon Holdings LLC and acquired all the equity of Symphony Icon, Inc., thereby reacquiring all rights to LX1031, LX1032, LX1033 and the other drug programs subject to the collaboration.

2 Aug 2010

WHO expert: Faster MDR-TB test should be made available to vulnerable populations

A new diagnostic tool that shortens the diagnosis of multidrug-resistant tuberculosis (MDR-TB) from eight weeks to two hours should be made available to vulnerable populations according to a WHO expert, Reuters reports.

31 Jul 2010

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Today, Formatech, Inc. announced that it has selected Femta's FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta's upcoming clinical trials.

31 Jul 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Amputation can be prevented when patients are treated by podiatric physicians: Study

Scientist invents new approach to boost body's response to vaccinations

FDA designates XOMA 052 orphan drug for Behcet's disease

Arthritis treatment costs more than $128 billion a year in the U.S.

Infinity reports $18.4 million total revenue for second-quarter 2010

Targacept licenses Cornerstone technology for inflammatory disorders program

Savient second-quarter net loss decreases to $5.0 million

Researchers identify TACI; MyD88 activates immune system against infection

Horizon Pharma files registration statement with U.S. SEC for proposed initial public offering

POZEN reports $16.2M net income for second-quarter 2010

Rigel reports net income of $27.0M for second-quarter 2010

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

International study of more than 60,000 women highlights additional risk associated with fractures

Disparities in cardiovascular disease risk linked to socioeconomic differences between races: Study

Osteologix grants Servier Research Group exclusive license to develop, commercialize NB S101

Lexicon acquires equity shares of Symphony Icon Holdings

WHO expert: Faster MDR-TB test should be made available to vulnerable populations

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in